- Nelson, Bryan S;
- Tierney, Camlin;
- Persaud, Deborah;
- Jao, Jennifer;
- Cotton, Mark F;
- Bryson, Yvonne;
- Coletti, Anne;
- Ruel, Theodore D;
- Spector, Stephen A;
- Reding, Christina;
- Bacon, Kira;
- Costello, Diane;
- Perlowski, Charlotte;
- Cruz, Maria Leticia Santos;
- Kosgei, Josphat;
- Majji, Sai;
- Yin, Dwight E;
- Jean-Philippe, Patrick;
- Chadwick, Ellen G;
- Team, for the IMPAACT P1115
We followed 54 infants with in utero HIV after initiating very early antiretroviral treatment. At weeks 24 and 48, ≥80% had CD4 ≥1500 cells/mm3 and CD4% ≥25%. Routine Pneumocystis jirovecii pneumonia prophylaxis in the first year of life may not be necessary for all very early treated infants.
Clinical trials registration
NCT02140255.